Aims: A deficit in parvalbumin (PV) neurons is found in schizophrenia and several animal models of the disease. In this preliminary study, we determined whether one such model, phencyclidine (PCP) administration, results in changes in DNA methylation in the rat PV gene (Pvalb) promoter. Methods: DNA from hippocampus and prefrontal cortex (PFC) from rats, which 6 weeks previously received either 2mg/kg PCP or vehicle for 7 days, underwent bisulphite pyrosequencing to determine methylation. Results: PCP administration induced significantly greater methylation at one of two Pvalb CpG sites in both PFC and hippocampus, while no significant difference was found in Long Interspersed Nucleotide Element-1, a global measure of DNA methylation. Conclusion: Subchronic PCP administration results in a specific hypermethylation in the Pvalb promoter which may contribute to PV deficits in this animal model of psychosis.
Introduction
The NMDA receptor antagonist phencyclidine (PCP) has been widely used in the investigation and modelling of psychotic illness. Sub-chronic administration of PCP to animals can induce brain metabolic and neurochemical changes [1] as well as behaviours [2] that mimic aspects of schizophrenia. Furthermore, this regime can also produce enduring deficits in several neurochemical markers that are also diminished in the brain in schizophrenia. These include the calcium binding protein parvalbumin (PV), which is expressed in a subgroup of GABAergic neurons, and in schizophrenia demonstrates reductions in frontal cortical regions [3] and, particularly profoundly, in the hippocampus [4] . Equivalent losses, typically greater than 50%, of PVimmunoreactive (PV-IR) cells, are also seen in the rat hippocampus following subchronic PCP [2] .
Deficits in immunostaining for PV-positive neurons have also been seen in other animal models that mimic some of the behavioural and also, in some models, the aetiological characteristics of schizophrenia. These include isolation rearing [5] , administration of neonatal endotoxin [6] and prenatal methylazoxymethanol (MAM) [7] in rats, as well as following other psychotogenic drugs including ketamine [8, 9] and amphetamine [10] .
The pathogenic mechanisms underlying these deficits in PV are unclear, although PCP can also induce decreases in PV gene (Pvalb) expression [1, 11] . We have speculated whether the PV deficit might relate to epigenetic changes induced by such pharmacological and environmental influences. One epigenetic factor is that of DNA methylation occurring at cytosine residues in CpG sequences; within promoter sequences this methylation can have major effects on gene expression [12] . There is evidence for dynamic effects on methylation of the mouse PV gene promoter sequence associated with manganese-induced neurotoxic damage [13] ; we hypothesised that changes in methylation of this sequence might relate to PV deficits in schizophrenia and its animal models. In this preliminary study we have determined the methylation status of CpG methylation sites within the equivalent sequence in frontal cortical (PFC) and hippocampal tissue from rats that had received subchronic PCP. The results were compared with a global measure of DNA methylation, that of Long Interspersed Nucleotide Element-1 (LINE-1) [14, 15] . We used the novel object recognition (NOR) paradigm to assess the efficacy of the treatment regime to induce cognitive deficits prior to the post-mortem analysis.
Material and Methods
Female Lister-hooded rats (200-230g) were housed in groups of 4-5 under standard laboratory conditions under a 12hr light: dark cycle, lights on at 0700hr. Rats were randomly assigned to two groups and either received vehicle, (distilled water, i.p.) or phencyclidine hydrochloride (PCP, 2 mg/kg, i.p. twice daily for 7-days) dissolved in distilled water. Behavioural testing was carried out in the light phase.
Rats were tested in the novel object recognition (NOR) paradigm and for locomotor activity 6 weeks after the last dose of PCP. Following the behavioural testing the brains were removed, flash frozen in isopentane and stored at -70%. These studies were carried out in accordance with the Animals Scientific Procedures Act (UK, 1986) and were approved by the University of Manchester ethical review panel.
The NOR paradigm has been described in detail elsewhere [16] . Briefly, following habituation to the test box, the rats are given an initial acquisition trial during which the animals are allowed to explore two identical objects for 3 min. After a 1 min interval when the animals are removed, one object is replaced with a novel object and the animals allowed to explore the objects again for 3 min. The exploration times of each object in each trial are recorded on video for subsequent blind scoring. NOR was determined by the discrimination index (DI) in the retention trial, calculated as: (t nt f ) / (t n + t f ) where t n and t f are times spent exploring the novel and familiar objects respectively. Data are expressed as mean ± SEM. (n= 9 per group) and were analysed by a one way ANOVA.
Genomic DNA was extracted from PFC and hippocampal tissue using QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA), was bisulphite-modified to convert unmethylated cytosine residues to uracil using the EpiTec Fast DNA Bisulphite Kit (Qiagen) with a calculated mean conversion of 99%. We identified a previously-studied [13] For LINE-1, a sequence of 4 CpGs was amplified [17] by PCR primers, as follows: as factors; significant effects were further investigated by post-hoc t-test.
Results
During the acquisition trial in the NOR paradigm both groups spent an equal time exploring the left and right objects. In the retention trial the vehicle-treated, but not PCP-treated, animals spent more time exploring the novel versus the familiar object resulting in a significant difference in the discrimination index (vehicle: 0.35±0.04 vs PCP: 0.08±0.04; t-test p<0.01). There was no significant difference in locomotor activity between the groups (data not shown).
Brain DNA extracts gave consistent results for methylation at the two CpG sites in the 
Discussion
In this preliminary study we have demonstrated a highly significant elevation in DNA methylation in one of two CpG sites in the promoter sequence of the PV gene in brain tissue taken from rats previously receiving a sub-chronic regime of PCP. It is well-established that such PCP administration can induce an enduring deficit of PV-IR neurons and a reduction in PV gene expression [18] , as well as producing cognitive deficits, demonstrated here by the reduction in NOR. The increase in Pvalb methylation is found not to reflect a general, global increase in DNA methylation, being seen in the absence of a significant change in LINE-1 methylation, and therefore appears to be a relatively gene-specific consequence of PCP administration.
The specific increase seen is of a similar magnitude to changes seen in other schizophrenia-associated genes in both human [19] and rat brain tissue [20] .
Generally, DNA methylation is inversely related to gene expression, as promoter sequence methylation could directly interfere with transcription factor binding sites and also indirectly cause gene silencing through methylated DNA binding proteins that recruit histone deacetylases, leading to chromatin condensation [21] .
The promoter activity of the sequence we have studied has been demonstrated [22, 23] , and the methylation of this sequence has previously been shown to be increased following challenge by another neurotoxic factor, that of manganese [13] .
These authors showed effects of maternal manganese exposure on epigenetic gene regulation, with Pvalb promoter hypermethylation and transcript downregulation at the weaning stage in the offspring.
The CpG sites studied here are at the 5' boundary of a large CpG island with a high density of both CpG sites and transcription factor recognition sequences. These include multiple binding sites for Nrf2, several close to CpG2 and further CpG sites within the CpG island. Thus methylation in this sequence could conceivably modify Nrf2 binding and its associated transcriptional activity. Nrf2 has been identified as a transcription factor important in antioxidant effects on gene expression [24] . Given that the disruptive effects of repeated administration of another NMDA antagonist, ketamine, on PV neurons are mediated through oxidative damage [8] and that a natural antioxidant and potent activator of Nrf2 can protect against PCP-induced cognitive dysfunction [25] , these findings provide an intriguing mechanistic link between oxidative damage and PV deficits due to PCP administration. 
Conclusion and Future Perspectives
This preliminary study demonstrates that sub-chronic PCP administration to rats 6 weeks previously, and resulting in a cognitive deficit, can also have a specific and enduring effect on DNA methylation in the promoter region of Pvalb. Much more needs to be done to fully understand the process and effects of this Pvalb promoter hypermethylation. It would be important to determine whether Pvalb methylation parallels the time course of PV deficits and the protective effects of antioxidant or other pharmacological intervention.
We have studied what is likely to be a functionally important sequence within the promoter region of Pvalb, but further sequences important in transcriptional activity need to be investigated. Although the finding is independent of one measure of global DNA methylation, it may well be that other specific genes may also demonstrate changes in DNA methylation, particularly those implicated in the GABAergic deficits following PCP administration such as those of GAD67 expression [27] and calbindin [28] . Most important would be to determine whether hypermethylation of the PV gene occurs in psychotic illness including schizophrenia, for which sub-chronic PCP administration can model both PV deficits and certain symptoms [29] .
Executive Summary

Background
• Subchronic phencyclidine (PCP) administration to rats can produce enduring deficits in the calcium binding protein parvalbumin (PV) in GABAergic neurons; these resemble equivalent deficits in schizophrenia.
• Effects on DNA methylation may contribute to these PV deficits.
Results
•
We found increased brain DNA methylation at one site in the PV gene promoter following subchronic PCP administration to rats.
• This increase in methylation is specific to a site within a transcription factor binding sequence.
• No differences were found in a global measure of DNA methylation.
Conclusion
• PCP sub-chronic administration to rats results in hypermethylation of a specific site in the promoter sequence of the PV gene.
• This hypermethylation may, through effects on transcription, contribute to the enduring reduction in PV following PCP administration.
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